テキサスにおける膠腫の臨床試験
テキサス内の拠点で、膠腫に関する26件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 他8件
被験者募集中第1/2相
12 Months – 21 Years · 全性別 · 2026/10/01更新 · NCT05099003A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center, Dallas
- Baylor College of Medicine, Houston
被験者募集中第1/2相
25歳以下 · 全性別 · 2026/09/25更新 · NCT04094610MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
- M D Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/25更新 · NCT03896568ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Texas Children's Hospital, Houston
被験者募集中第2相
12 Months – 39 Years · 全性別 · 2026/09/21更新 · NCT06838676MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas
- M D Anderson Cancer Center, Houston
被験者募集中
18歳以上 · 全性別 · 2026/09/14更新 · NCT04373720Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma
- M D Anderson Cancer Center, Houston
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT04771806Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
- The University of Texas M. D. Anderson Cancer Center, Houston
被験者募集中第1相
36 Months · 全性別 · 2026/09/09更新 · NCT07076498Targeted Pediatric High-Grade Glioma Therapy
- Texas Children's Hospital, Houston
被験者募集中観察研究
12 Months – 39 Years · 全性別 · 2026/09/08更新 · NCT05839379HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- MD Anderson Cancer Center, Houston
被験者募集中第1相
36 Months – 22 Years · 全性別 · 2026/09/04更新 · NCT03911388Study of Olutasidenib and Temozolomide in HGG
- Texas Children's Hospital, Houston
被験者募集中第2相
12歳〜39歳 · 全性別 · 2026/09/01更新 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- University of Texas Health Mays Cancer Center, San Antonio
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Texas Children's Hospital, Houston
被験者募集中第2相
3歳〜39歳 · 全性別 · 2026/08/24更新 · NCT05096481Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- M D Anderson Cancer Center, Houston
被験者募集中観察研究
全年齢 · 全性別 · 2026/08/21更新 · NCT01772771Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
- University Of Texas Southwestern Medical Center, Dallas
被験者募集中第1相
1歳〜25歳 · 全性別 · 2026/08/18更新 · NCT04485559Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Houston
- Research Site, San Antonio
被験者募集中第1/2相
18歳〜130歳 · 全性別 · 2026/08/12更新 · NCT05417594Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
- Excel Diagnostics & Nuclear Oncology Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/07更新 · NCT07733674C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
- Texas Children's Hospital, Houston
被験者募集中第1相
12 Months – 25 Years · 全性別 · 2026/08/03更新 · NCT04099797A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Baylor Scott & White Research Institute, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center, Temple
被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Texas Children's Hospital, Houston
被験者募集中早期第1相健康なボランティア歓迎
1歳〜21歳 · 全性別 · 2026/06/29更新 · NCT06333899Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
- M D Anderson Cancer Center, Houston
被験者募集中早期第1相
18歳以上 · 全性別 · 2026/06/12更新 · NCT05804227Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Texas Children's Hospital, Houston
被験者募集中第2相
12 Months – 39 Years · 全性別 · 2026/05/29更新 · NCT05843253A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/20更新 · NCT06326411Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/13更新 · NCT06810544A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Texas Children's Hospital, Houston
被験者募集中早期第1相
21歳以下 · 全性別 · 2026/03/18更新 · NCT04655404Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
- The Cancer Therapy and Research Center at UTHSCSA, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2025/03/30更新 · NCT05460507Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- UT Southwestern Medical Center, Dallas
- The Cancer Therapy and Research Center at UTHSCSA, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/03/26更新 · NCT01906385ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。